A Systematic Review and Economic Evaluation of Pegylated Liposomal Doxorubicin Hydrochloride for Ovarian Cancer

Health Technology Assessment - United Kingdom
doi 10.3310/hta6230
Full Text
Abstract

Available in full text

Date
Authors
Publisher

National Institute for Health Research

Related search

Emerging Pharmacotherapies in Ovarian Cancer: Focus on Pegylated Liposomal Doxorubicin

Clinical Medicine Reviews in Women's Health
2010English

Non‑pegylated Liposomal Doxorubicin for Patients With Recurrent Ovarian Cancer: A Multicentric Phase II Trial

Oncology Letters
Cancer ResearchOncology
2016English

A Retrospective Analysis of Pegylated Liposomal Doxorubicin in Ovarian Cancer: Do We Still Need It?

Journal of Ovarian Research
GynecologyOncologyObstetrics
2013English

Pmd77 - Economic Evaluation of Screening and Prevention Strategies for Ovarian Cancer: A Systematic Review

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Efficacy and Safety of Non-Pegylated Liposomal Doxorubicin in Metastatic Breast Cancer Therapy

OnCOReview
Oncology
2017English

Pharmacokinetics and Efficacy of PEGylated Liposomal Doxorubicin in an Intracranial Model of Breast Cancer

PLoS ONE
Multidisciplinary
2013English

Squamous Cell Carcinoma of the Oral Cavity in a Woman With a 9-Year History of Ovarian Cancer: Is Exposure to Pegylated Liposomal Doxorubicin a Factor?

Oncologist
Cancer ResearchMedicineOncology
2014English

A Phase II Study of Bortezomib in Combination With Pegylated Liposomal Doxorubicin for Acute Myeloid Leukemia

American Journal of Hematology
Hematology
2019English

Pegylated Liposomal Doxorubicin in the Treatment of Primary Cutaneous T-Cell Lymphomas

Haematologica
Hematology
2007English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy